β-lactam derivatives as inhibitors of human cytomegalovirus protease

Journal of Medicinal Chemistry

Volumn 41, Issue 15, 1998, Pages 2882-2891

  Yoakim, Christiane ^a   Ogilvie, William W ^a   Cameron, Dale R ^a   Chabot, Catherine ^a   Guse, Ingrid ^a   Haché, Bruno ^a   Naud, Julie ^a   O'Meara, Jeff A ^a   Plante, Raymond ^a   Déziel, Robert ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM DERIVATIVE; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; ARTICLE; CYTOMEGALOVIRUS; DERIVATIZATION; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; NONHUMAN; OPPORTUNISTIC INFECTION; PROTEIN DOMAIN; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; BETA-LACTAMS; CATTLE; CELL LINE, TRANSFORMED; CYTOMEGALOVIRUS; HUMANS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; SWINE; UREA;

EID: 15644380718     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980131z     Document Type: Article

References (41)

1. Alford, C. A.; Britt, W. J. In The human Herpesviruses; Roizman, B., Whitley, R. J., Lopez, C., Eds.; Raven Press: New York, 1993; pp 227-255.
2. (a) Xiong, X.; Smith, J. L.; Chen, M. S. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob. Agents Chemother. 1997, 41, 594-599 and references therein.
3. (b) Xiong, X.; Smith, L. S.; Kim, C.; Huang, E.; Chen, M. S. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegalovirus DNA polymerase. Biochem. Pharmacol. 1996, 51, 1563-1567 and references therein.
4. (a) Welch, A. R.; McNally, L. M.; Gibson, W. Cytomegalovirus assembly protein nested gene familly: four 3′-coterminal transcripts encode four in-frame, overlapping proteins. J. Virol. 1991, 65, 4091-4100.
5. (b) Welch, A. R.; Woods, A. S.; McNally, L. M.; Cotter, R. J.; Gibson, W. A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 10792-10796.
6. (a) Gibson, W.; Welch, A. R.; Hall, M. R. T. Assemblin, a herpes virus serine maturational proteinase and new molecular target for antivirals. Perspect. Drug Discovery Des. 1994, 2, 413-426 and references therein.
7. (b) Holwerda, B. C. Herpesevirus proteases: targets for novel antiviral drugs. Antiviral Res. 1997, 35, 1-21.
8. Rawlings, N. D.; Barrett, A. J. Families of serine proteases. Methods Enzymol. 1994, 244, 19-61.
9. (a) Tong, L.; Qian, C.; Massariol, M.-J.; Bonneau, P. R.; Cordingley, M. G.; Lagacé, L. A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease. Nature 1996, 272-275.
10. (b) Qiu, X.; Culp, J. S.; DiLella, A. G.; Hellmig, B.; Hoog, S. S.; Janson, C. A.; Smith, W. W.; Abdel-Meguid, S. S. Unique fold and active site in cytomegalovirus protease. Nature 1996, 275-279.
11. (c) Shieh, N.-S.; Kurumball, R. G.; Stevens, A. M.; Stegeman, R. A.; Sturman, E. J.; Pak, J. Y.; Wittwer, A. J.; Palmier, M. O.; Wiegand, R. C.; Holwerda, B. C.; Stallings, W. C. Three-dimensional structure of human cytomegalovirus protease. Nature 1996, 279-282.
12. (d) Chen, P.; Tsuge, H.; Almassy, R. J.; Gribskov, C. L.; Katoh, S.; Vanderpool, P. L.; Margosiak, S. A.; Pinko, C.; Matthews, D. A.; Kan, C.-C. Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad. Cell 1996, 86, 835-843.
13. Ogilvie, W.; Bailey, M.; Poupart, M.-A.; Abraham, A.; Bhavsar, A.; Bonneau, P.; Bordeleau, J.; Bousquet, Y.; Chabot, C.; Duceppe, J.-S.; Fazal, G.; Goulet, S.; Grand-Maître, C.; Guse, I.; Halmos, T.; Lavallée, P.; Leach, M.; Malenfant, E.; O'Meara, J.; Plante, R.; Plouffe, C.; Poirier, M.; Soucy, F.; Yoakim, C.; Déziel, R. Peptidomimetic inhibitors of the human cytomegalovirus protease. J. Med. Chem. 1997, 40, 4113-1435.
14. For nonpeptidic inhibitors of HCMV protease, see: (a) Flynn, D. L.; Becker, D. P.; Dilworth, V. M.; Highkin, M. K.; Hippenmeyer, P. J.; Housman, K. A.; Levine, L. M.; Li, M.; Moormann, A. E.; Rankin, A.; Toth, M. V.; Villamil, C. I.; Wittwer, A. J.; Holwerda, B. C. The herpesvirus protease: Mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease. Drug Des. Discovery 1997, 15, 3-15. (b) Jarvest, R. L.; Connor, S. C.; Gorniak, J. G.; Jennings, L. J.; Serafinowska, H. T.; West, A. Potent selective thienoxazolinone inhibitors of herpes proteases. Bioorg. Med. Chem. Lett. 1997, 7, 1733-1738. (c) Abood, N. A.; Schretzman, L. A.; Flynn, D. A.; Houseman, K. A.; Wittwer, A. J.; Dilworth, V. M.; Hippenmeyer, P. J.; Holwerda, B. C. Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture. Bioorg. Med. Chem. Lett. 1997, 7, 2105-2108. See also those papers cited in ref 7.
15. For nonpeptidic inhibitors of HCMV protease, see: (a) Flynn, D. L.; Becker, D. P.; Dilworth, V. M.; Highkin, M. K.; Hippenmeyer, P. J.; Housman, K. A.; Levine, L. M.; Li, M.; Moormann, A. E.; Rankin, A.; Toth, M. V.; Villamil, C. I.; Wittwer, A. J.; Holwerda, B. C. The herpesvirus protease: Mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease. Drug Des. Discovery 1997, 15, 3-15. (b) Jarvest, R. L.; Connor, S. C.; Gorniak, J. G.; Jennings, L. J.; Serafinowska, H. T.; West, A. Potent selective thienoxazolinone inhibitors of herpes proteases. Bioorg. Med. Chem. Lett. 1997, 7, 1733-1738. (c) Abood, N. A.; Schretzman, L. A.; Flynn, D. A.; Houseman, K. A.; Wittwer, A. J.; Dilworth, V. M.; Hippenmeyer, P. J.; Holwerda, B. C. Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture. Bioorg. Med. Chem. Lett. 1997, 7, 2105-2108. See also those papers cited in ref 7.
16. For nonpeptidic inhibitors of HCMV protease, see: (a) Flynn, D. L.; Becker, D. P.; Dilworth, V. M.; Highkin, M. K.; Hippenmeyer, P. J.; Housman, K. A.; Levine, L. M.; Li, M.; Moormann, A. E.; Rankin, A.; Toth, M. V.; Villamil, C. I.; Wittwer, A. J.; Holwerda, B. C. The herpesvirus protease: Mechanistic studies and discovery of inhibitors of the human cytomegalovirus protease. Drug Des. Discovery 1997, 15, 3-15. (b) Jarvest, R. L.; Connor, S. C.; Gorniak, J. G.; Jennings, L. J.; Serafinowska, H. T.; West, A. Potent selective thienoxazolinone inhibitors of herpes proteases. Bioorg. Med. Chem. Lett. 1997, 7, 1733-1738. (c) Abood, N. A.; Schretzman, L. A.; Flynn, D. A.; Houseman, K. A.; Wittwer, A. J.; Dilworth, V. M.; Hippenmeyer, P. J.; Holwerda, B. C. Inhibition of human cytomegalovirus protease by benzoxazinones and evidence of antiviral activity in cell culture. Bioorg. Med. Chem. Lett. 1997, 7, 2105-2108. See also those papers cited in ref 7.
17. Finke, P. E.; Shah, S. K.; Fletcher, D. S.; Ashe, B. M.; Brause, K. A.; Chandelier, G. O.; Dellea, P. S.; Hand, K. M.; Maycock, A. L.; Osinga, D. G.; Underwood, D. J.; Weston, H.; Davies, P.; Doherty, J. B. Orally active β-lactam inhibitors of human leukocyte elastase. Stereospecific synthesis and structure -activity relationships for 3,3-dialkylazetidin-2-ones. J. Med. Chem. 1995, 38, 2449-2462.
18. 0 with monocyclic β-lactams. Bioorg. Med. Chem. Lett. 1998, 8, 1437.
19. Loewe, M. F.; Cvetovich, R. J.; Hazen, G. G. An efficient β-amino acid cyclodehydration using methanesulfonyl chloride to thienamycin intermediate 3-(1-hydroxyethyl)-4-(methoxycarbonylmethyl)-azetidin-2-one. Tetrahedron Lett. 1991, 32, 2299-2302.
20. Thavonakham, B. A practical synthesis of ureas from phenyl carbamates. Synthesis 1997, 1189.
21. Ohno, K.; Nishiyama, H.; Nagase, H. A mild methylation of alcohols with diazomethane catalyzed by silica gel. Tetrahedron Lett. 1979, 4405-4406.
22. Rehders, F.; Hoppe, D. Synthesis of dihydroethylene isosteres of dipeptides. Enantiomerically and diastereomerically pure 2-alkyl-5-amino-3-dimethylphenylsilyl-4-octanolides from (S)-N,N-dibenzyl-leucinal. Synthesis 1992, 859-870.
23. Bonneau, P.; et al. Unpublished results.
24. For a discussion, see: Firestone, R. A.; Barker, P. L.; Pisano, J. M.; Ashe, B. M.; Dahlgren, M. E. Monocyclic β-lactam inhibitors of human leukocyte elastase. Tetrahedron 1990, 46, 2255-2262.
25. (a) Green, B. G.; Chabin, R.; Mills, S.; Underwood, D. J.; Shah, S. K.; Kuo, D.; Gale, P.; Maucock, A. L.; Liesch, J.; Burgey, C. S.; Doherty, J. B.; Dorn, C. P.; Finke, P. E.; Hagmann, W. K.; Hale, J. J.; MacCoss, M.; Westler, W. M.; Knight, W. B. Mechanism of inhibition of human leucocyte elastase by β-lactams. 2. Stability, reactivation kinetics, and products of β-lacam-derived E-I complexes. Biochemistry 1995, 34, 14331-14343.
26. (b) Underwood, D. J.; Green, B. G.; Chabin, R.; Mills, S.; Doherty, J. B.; Finke, P. E.; MacCoss, M.; Shah, S. K.; Burgey, C. S.; Dickinson, T. A.; Griffin, P. R.; Lee, T. E.; Swiderek, K. M.; Covey, T.; Westler, W. M.; Knight, W. B. Mechanism of inhibition of human leucocyte elastase by β-lactams. 3. Use of electrospray -ionization mass spectrometry and two-dimensional NMR techniques to identify β-lactam-derived E-I complexes. Biochemistry 1995, 34, 14344-14355.
27. m) on 271 determinations.
28. 1/2) was determined in the media used for the plaque reduction assay (see the Experimental Section). The values reported are the average of at least three determinations rounded to the nearest 0.5 day.
29. Shah, S. K.; Dorn, C. P., Jr.; Finke, P. E.; Hale, J. J.; Hagmann, W. K.; Brause, K. A.; Chandler, G. O.; Kissinger, A. L.; Ashe, B. M.; Weston, H.; Knight, W. B.; Maycock, A. L.; Dellea, P. S.; Fletcher, D. S.; Hand, K. M.; Mumford, R. A.; Underwood, D. J.; Doherty, J. B. Orally active β-lactam inhibitors of human leucocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones. J. Med. Chem. 1992, 35, 3745-3754. See also ref 9.
30. (a) Shah, S. K.; Finke, P. E.; Brause, K. A.; Chandler, G. O.; Ashe, B. M.; Weston, H.; Maycock, A. L.; Mumford, R. A.; Doherty, J. B. Monocyclic β-lactam inhibitors of human leucocyte elastase. Stereospecific synthesis and activity of 3,4-disubstituted-2-azetidinones. Bioorg. Med. Chem. Lett. 1993, 3, 2295-2298.
31. (b) Doherty, J. B.; Shah, S. K.; Finke, P. E.; Dorn, C. P., Jr.; Hagman, W. K.; Hale, J. J.; Kissinger, A. L.; Thompson, K. R.; Brause, K.; Chandler, G. O.; Knight, W. B.; Maycock, A. L.; Ashe, B. M.; Weston, H.; Gale, P.; Mumford, R. A.; Anderson, O. F.; Williams, H. R.; Nolan, T. E.; Frankenfield, D. L.; Underwood, D.; Vyas, K. P.; Kari, P. H.; Dahlgren, M. E.; Mao, J.; Fletcher, D. S.; Dellea, P. S.; Hand, K. M.; Osinga, D. G.; Peterson, L. B.; Williams, D. T.; Metzger, J. M.; Bonney, R. J.; Humes, J. L.; Pacholok, S. P.; Hanlon, W. A.; Opas, E.; Stolk, J.; Davies, P. Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: A potent, orally active monocyclic β-lactam inhibitor of human polymorphonuclear leukocyte elastase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8727-8731. See also ref 9.
32. Detailed descriptions of these assays can be found in ref 7.
33. 50 values of greater than 75 μM.
34. Because of the possibility of steric clashes between the enzyme and inhibitor, and to eliminate interference by potential hydrogen bonding, compounds 48 and 52 were excluded from this analysis.
35. Hansch, C.; Leo, A.; Unger, S. H.; Kim, K. H.; Nikaitani, D.; Lien, E. J. "Aromatic" substituent constants for structure - activity correlations. J. Med. Chem. 1973, 16, 1207-1216.
36. Williams, V. E.; Lemieux, R. P.; Thatcher, G. R. J. Substituent effects on the stability of arene-arene complexes: An AM1 study of the conformational equilibria of cis-1,3-Diphenylcyclohexanes. J. Org. Chem. 1996, 61, 1927-1933.
37. 50 > 250 μM.
38. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical model J. Am. Chem. Soc. 1985, 107, 3902-3909.
39. Wavefunction Inc., 18401 Von Karman Ave, #370, Irvine, CA 92715.
40. Bonneau, P. R.; Plouffe, C.; Pelletier, A.; Wernic, D.; Poupart, M.-A. Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure - activity relationship studies. Anal. Biochem. 1998, 255, 59-65.
41. m) on 82 determinations.